TLX
insider transactionsTelix Pharmaceuticals Ltd — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
+67.9K
67.9K buy · 0 sell
Net value · 90d
$996.7K
$996.7K in · $0 out
Sentiment · 90d
Net buying
100% buying · 0% selling
Open-market trades · 90d
2
67.9K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
MD & Group CEO
$497.2K
33.4K sh · $14.87
Own +0%
-
Buy·P
MD & Group CEO
$499.6K
34.5K sh · $14.48
Own +0%
-
Exercise·M
Group Chief Financial Officer
$0
1.1K sh
Own New
-
Exercise·M
Group Chief Financial Officer
$0
1.1K sh
Own +10%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 29, 2026 | Christian Behrenbruch KEY | Buy P | 33.4K | $497.2K |
| Apr 28, 2026 | Christian Behrenbruch KEY | Buy P | 34.5K | $499.6K |
| Mar 29, 2026 | Darren Charlton Smith KEY | Exercise M | 1.1K | $0 |
| Mar 29, 2026 | Darren Charlton Smith KEY | Exercise M | 1.1K | $0 |
About TLX insider trading
This page tracks insider transactions for Telix Pharmaceuticals Ltd (TLX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.